Truist raised the firm’s price target on Cigna (CI) to $385 from $375 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm’s models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm’s expectation of a better environment, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Apple, Starbucks upgraded: Wall Street’s top analyst calls
- Cigna price target raised to $384 from $360 at Mizuho
- Cigna initiated with a Buy at Guggenheim
- Trump Weekly: U.S. announces new tariffs, China responds with their own
- FTC halts lawsuit against PBMs after Trump fires commissioners, WSJ says